A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease.

MLA

Przepiorka, D., et al. “A Phase II Study of BTI-322, a Monoclonal Anti-CD2 Antibody, for Treatment of Steroid-Resistant Acute Graft-versus-Host Disease.” Blood, vol. 92, no. 11, Dec. 1998, pp. 4066–71. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=9834211&authtype=sso&custid=ns315887.

APA

Przepiorka, D., Phillips, G. L., Ratanatharathorn, V., Cottler-Fox, M., Sehn, L. H., Antin, J. H., LeBherz, D., Awwad, M., Hope, J., & McClain, J. B. (1998). A phase II study of BTI-322, a monoclonal anti-CD2 antibody, for treatment of steroid-resistant acute graft-versus-host disease. Blood, 92(11), 4066–4071.

Chicago

Przepiorka, D, G L Phillips, V Ratanatharathorn, M Cottler-Fox, L H Sehn, J H Antin, D LeBherz, M Awwad, J Hope, and J B McClain. 1998. “A Phase II Study of BTI-322, a Monoclonal Anti-CD2 Antibody, for Treatment of Steroid-Resistant Acute Graft-versus-Host Disease.” Blood 92 (11): 4066–71. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=9834211&authtype=sso&custid=ns315887.